Stocktoria
Bayer Aktiengesellschaft BAYN.DE
DE · Deutsche Börse Xetra · XETR · stock · Healthcare · website
Bayer Aktiengesellschaft financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €45.6B | €46.6B | €47.6B | €50.7B |
| Gross profit | €26.8B | €25.3B | €27.9B | €30.9B |
| R&D expense | €5.8B | €6.2B | €5.4B | €6.6B |
| SG&A expense | €14.7B | €15.9B | €14.9B | €16.9B |
| Operating income | €6.1B | €3.3B | €8.0B | €7.3B |
| Interest expense | €2.3B | €2.4B | €2.0B | €1.9B |
| Income tax | €466.0M | €212.0M | €1.3B | €504.0M |
| Net income | -€3.6B | -€2.6B | -€2.9B | €4.2B |
| EPS (diluted) | €-3.68 | €-2.60 | €-2.99 | €4.22 |
| Operating cash flow | €5.9B | €7.4B | €5.1B | €7.1B |
| Free cash flow | €3.4B | €4.6B | €2.4B | €4.1B |
| Cash & equivalents | €6.7B | €6.2B | €5.9B | €5.2B |
| Inventory | €12.3B | €13.4B | €13.9B | €13.6B |
| Goodwill | €28.1B | €30.0B | €32.3B | €39.6B |
| Total assets | €104.5B | €110.8B | €116.3B | €124.9B |
| Total debt | €36.5B | €40.7B | €42.9B | €41.3B |
| Total liabilities | €78.5B | €78.8B | €83.2B | €86.0B |
| Shareholders' equity | €25.9B | €31.9B | €32.9B | €38.8B |
| Share buybacks | €14.0M | €16.0M | €24.0M | €25.0M |
Growth · year-over-year · Revenue CAGR -3.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -2.2% | -2.2% | -6.1% | — |
| Net income growth | — | — | -170.9% | — |
| EPS growth | — | — | -170.9% | — |
| Free cash flow growth | -25.0% | +94.0% | -42.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · DE · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.